Panbela Therapeutics Operating Income

Panbela Therapeutics (PBLA) currently reports a operating income of $-44M as of September 2024. That compares with $-32M in the prior-year period — down 40.4% year over year. Use the charts on this page to explore Panbela Therapeutics's operating income history and peer comparisons.

Panbela Therapeutics's operating income decreased from $-32M to $-44M — a 40.4% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Panbela Therapeutics reported $-44M in operating income as of September 2024. That compares with $-32M in the prior-year period — down 40.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-44M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Panbela Therapeutics, and consider following PBLA for alerts when major investors trade the stock.

Panbela Therapeutics is classified in the Technology sector. On operating income, it currently shows $-44M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Technology are usually more informative than comparing PBLA with unrelated industries.